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Background: Malignant pleural effusions (MPEs) remain a common problem, with 40,000 new cases in the United
Kingdom each year and up to 250,000 in the United States. Traditional management of MPE usually involves an
inpatient stay with placement of a chest drain, followed by the instillation of a pleural sclerosing agent such as talc,
which aims to minimise further fluid build-up. Despite a good success rate in studies, this approach can be expensive,
time-consuming and inconvenient for patients. More recently, an alternative method has become available in the form
of indwelling pleural catheters (IPCs), which can be inserted and managed in an outpatient setting. It is currently
unknown whether combining talc pleurodesis with IPCs will provide improved pleural symphysis rates over those
of IPCs alone.
Methods/Design: IPC-PLUS is a patient-blind, multicentre randomised controlled trial (RCT) comparing the
combination of talc with an IPC to the use of an IPC alone for inducing pleurodesis in MPEs. The primary outcome is
successful pleurodesis at five weeks post-randomisation. This study will recruit 154 patients, with an interim analysis for
efficacy after 100 patients, and aims to help to define the future gold standard for outpatient management of patients
with symptomatic MPEs.
Discussion: IPC-PLUS is the first RCT to examine the practicality and utility of talc administered via an IPC. The study
remains in active recruitment and has the potential to significantly alter how patients requiring pleurodesis for MPE are
approached in the future.
Trial registration: This trial was registered with Current Controlled Trials (identifier: ISRCTN73255764) on 23
August 2012.
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Malignant pleural effusions (MPEs) are a common com-
plication of many cancers, with 40,000 new cases in the
United Kingdom each year and up to 250,000 in the
United States [1]. Their presence usually indicates meta-
static disease, and hence possibly a poorer prognosis.
The traditional management of MPE involves inpatient
insertion of a chest drain, to ensure fluid drainage and
pleural apposition, before the instillation of a sclerosant
substance to cause pleural inflammation and adhesion,
also known as pleurodesis. Many substances can be used
as a pleural irritant, although by far the most commonly
used worldwide is talc, which has been shown to be su-
perior to numerous alternatives [2].
Quoted pleurodesis success rates are typically high
with talc, ranging from 81 to 100% [3], although these
figures may vary considerably in real-world practice due
to differences between clinicians and between the prac-
tices of individual centres. To achieve such high efficacy,
a patient typically requires admission for the insertion of
a chest tube and drainage. Only once the pleural space is
felt to be dry is the talc inserted. This usually requires
an inpatient stay of five to seven days [4,5], which can
have a significant health economic impact, as well as the
potential to impair the quality of remaining life for pa-
tients. Following the widespread use of large-particle
talc, the side effects of pleurodesis have tended to be
minor, the commonest of which are fever, pain and
gastrointestinal upset [2,6,7], although there have been
rare cases of empyema [8].
The main drawback of the traditional method of pleur-
odesis is the length of hospital stay and the inconveni-
ence to patients. In more recent years, indwelling pleural
catheters (IPCs) have become more widely used and
may the potential to alleviate these problems.
IPCs are silastic tubes, which have the potential to be
left in place for weeks to months after being tunnelled
under the skin. They can be inserted under local anaes-
thetic or at thoracoscopy, and are usually performed as a
day case. Once at home, the aim is to drain fluid regu-
larly (usually three times per week) in the patient’s own
environment. This maximises the opportunity for pleural
apposition and adhesion, which potentially leads to
complete pleurodesis. Drainage can be performed by
anyone with appropriate training, including the patient,
but is often managed by district nursing teams.
IPCs have been shown to be effective in the manage-
ment of MPEs, although there is a paucity of evidence
comparing them directly to talc pleurodesis. In a retro-
spective series of 250 cases, almost 90% of patients expe-
rienced complete or partial relief of dyspnoea [9], a
finding bettered in a later study in which all patients ex-
perienced improvement [10]. Indwelling drains have also
been shown to improve other outcomes, such as lengthof hospital stay and future admissions, even in compari-
son to talc pleurodesis [4,11]. Despite the need for pro-
prietary drainage kits, they may also be cheaper overall
to healthcare providers, if used for limited periods of
time [12].
Regardless of patients’ short life expectancies, this is
an achievable goal as IPCs can often be removed follow-
ing sustained reduction in drainable fluid volumes, a
reliable surrogate indicator for pleurodesis. Such spon-
taneous pleurodesis generally occurs in around 50% of
cases [4,10,13] and is heavily influenced by the under-
lying tumour type [14], although rates as high as 70%
were reported in one study [15]. The presence of
‘trapped lung’ (usually due to central airways obstruction
or visceral pleural fibrosis) can lead to incomplete ex-
pansion following pleural fluid drainage, which no doubt
influenced the variability of the time to pleurodesis in
these studies. Indeed, in patients with trapped lung,
the persistent failure of pleural apposition makes the
achievement of any degree of pleurodesis much less
likely overall, meaning regular fluid management with
an IPC may be the only feasible approach to their care.
However, IPCs are not without drawbacks. There may
be significant pain associated with the immediate and
short-term post-procedure period, and in some cases
pleural tract metastases have been documented [16].
Complications including empyema formation (3%), sec-
ondary fluid loculation (12%) and cellulitis (2%) have
also been reported [9]. Nevertheless, meta-analysis data
has shown IPCs are generally safe to use, with an overall
complication rate of 12.5%.
It would seem, therefore, that the optimal approach to
the management of MPEs should be the combination of
talc instillation, to achieve the highest pleurodesis rates
and long-term fluid prevention, and placement of an
IPC to allow greater convenience and quality of life for
the patient. This should also theoretically lead to re-
duced overall healthcare costs when compared to either
individual method. Despite the potential for combining
fluid management approached being recognised in the
literature, [17] there have been no studies to date to test
this hypothesis, although ambulatory pleurodesis for ma-
lignant effusions was attempted in one small series by
Saffran et al. [18]. In this study, a closed-system pigtail
catheter was inserted and pleurodesis was attempted at a
later date using four grams of talc. Patients were man-
aged as outpatients and the authors describe their
method as being a viable alternative to traditional in-
patient management. However, patient numbers were
limited to 10 and there was no attempt at randomisa-
tion. The study took place before the widespread intro-
duction of IPCs.
The IPC-PLUS trial aims to test the hypothesis that
the combination of talc in addition to IPCs is superior
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has the potential to significantly affect, on a global scale,
the way in which such effusions are managed in the
future.
Methods/Design
Study questions
Our primary research question is, ‘In patients with a
proven MPE, does the use of talc as a sclerosant in con-
junction with an IPC increase the number of patients
achieving successful pleurodesis, when compared to
using an IPC alone?’
Our secondary research questions are as follows:
1. Does using talc and an IPC together alter the
amount of pain and breathlessness a patient
experiences, when compared to using an IPC alone?
2. Does the use of talc and an IPC together alter a
patient’s quality of life, when compared to using an
IPC alone?
3. What are the medical complications of using talc in
conjunction with an IPC?
4. What are the logistical and clinical difficulties with
using talc in conjunction with an IPC?
5. Does the combination of talc and an IPC together
influence the degree of fluid septation and loculation
seen on thoracic ultrasound?
6. Does the baseline level of serum brain natriuretic
peptide (BNP) correlate with the volume of pleural
fluid drained and chance of successful pleurodesis?
7. Does pleural elastance during initial drainage
correlate with lung entrapment and the chance of
successful pleurodesis?
8. Is using talc in combination with IPC cost-effective
when compared to IPC alone?
Sample size and power calculation
Talc pleurodesis alone has been shown to be up to 90%
efficacious in trial conditions [3], and we expect the
combination of talc and IPC to be at least as effective as
talc alone. IPCs used alone have a more variable range
for pleurodesis efficacy, but suggest an average rate of
around 50%.
Therefore, in order to detect a 25% difference in pleur-
odesis success at five weeks (using conservative esti-
mates of 60% IPC alone versus 85% IPC and talc) with
90% power, a 5% significance level and 5% loss to follow-
up, we would require 154 patients (77 in each arm). An
interim analysis for efficacy will take place after 100 pa-
tients are randomised.
Ethics, approvals and sponsorship
The study is sponsored in the United Kingdom by North
Bristol NHS Trust, and has been granted the necessary(national) approvals by both the Oxford A Research Eth-
ics Committee (approval number: 12/SC/0242) and the
Medicines and Healthcare Products Regulatory Agency
(MHRA) (EudraCT number: 2012-000599-40).Investigational product: Novatech Steritalc®
Medicinal sterile talc as used in this trial is mined in
Luzenac, France. It is marketed in the United Kingdom
as Steritalc® and imported by GB UK Healthcare Ltd
(Selby, UK). Talc is a naturally occurring mineral which,
when processed for medical use as Steritalc, takes the
form of a white powder of controlled particle size
(graded). It is not licensed in the United Kingdom but is
commonly used for the induction of pleurodesis, usually
to prevent recurrence of MPEs or pneumothoraces. Me-
dicinal talc has been licensed by the Food and Drug Ad-
ministration (FDA) in the United States since 2003.
Prior to introduction into the pleural cavity it is recon-
stituted into slurry using an inert solvent such as 0.9%
saline. The typical dose of talc is two to four grams.
Common side effects following pleural administration of
talc are mild pleuritic pain and low-grade fever.Study setting and design
The IPC-PLUS study is a non-commercial, patient-blind,
multicentre, randomised controlled trial of a medicinal
product. Patients will be recruited from multiple centres
within the United Kingdom. The trial is supported by
the appropriate local and regional cancer networks.
Clinical care, drain insertion and imaging will be pro-
vided by local medical professionals at the patients’ base
hospitals or appropriate satellite centres. Further care
will be provided by ward and specialist nurses in these
centres, who will also be available for telephone support.
Routine drainage of pleural fluid will take place in the
community and at follow-up visits. All drainages up to
the 28-day post-randomisation visit will be performed by
appropriately trained medical staff such as district
nurses, lung cancer specialist nurses or research nurses.
After this, drainages may be performed by anyone who
has been appropriately trained (except the patient
themselves).Patient population
Trial patients will be recruited from those presenting
with symptomatic MPEs. As part of their normal clinical
care, it will have been decided that outpatient treatment
with an IPC is the most appropriate strategy for fluid
management.Inclusion criteria
The inclusion criteria for this trial are as follows:
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regional level to require an IPC, defined as pleural
fluid in the context of one of the following: a
histocytologically proven pleural malignancy; an
otherwise unexplained pleural effusion in the
context of clinically proven cancer elsewhere or a
radiologically proven pleural malignancy, as
diagnosed in normal clinical practice on thoracic
CT, in the absence of histocytological proof.
2. Expected survival of more than two months and the
Eastern Co-operative Oncology Group/World
Health Organisation (ECOG/WHO) performance
status of two or more. Patients with a performance
status of three may be included if it is felt that
removal of the pleural fluid would improve their
performance status to two or better.
3. Written informed consent to trial participation.
Exclusion criteria
The exclusion criteria for this trial are as follows:
1. Aged under 18 years.
2. Females who are pregnant or lactating.
3. Patient is unable to provide informed consent.
4. Previous attempts at pleurodesis have been made
within the last 56 days on the same side as the
effusion requiring management.
5. Previously documented adverse reaction to talc or
lidocaine.
6. Community services are unable to drain the IPC at
least twice per week.
7. Evidence of extensive lung entrapment on a chest
X-ray or computed tomography (CT) scan, or
significant fluid loculation on an ultrasound scan, to
a level which would normally be a contraindication
to attempted talc pleurodesis or IPC insertion.
8. Other contraindication to IPC insertion.
9. Patient has no access to a telephone.
Screening and consent
Patients will be screened using the inclusion and exclu-
sion criteria as described above. Screening logs docu-
menting reasons for exclusions will be kept throughout
the trial. Those who may be suitable for an IPC will have
this option discussed in a normal outpatient or inpatient
setting, where they will also be given the option of par-
ticipating in the IPC-PLUS trial. Eligible patients will be
invited to participate on a consecutive basis, and will be
provided with an information leaflet at the earliest op-
portunity. They will be allowed sufficient time, as deter-
mined by the patient, to fully consider trial entry, as well
as to ask questions of investigators. Written informed
consent to trial participation will be obtained prior to
enrolment. Consent must be taken by a member of thetrial team and should take place before the placement of
the patient’s IPC.
Trial interventions
The trial interventions are summarised in Table 1 and in
Figure 1 (trial flow chart).
Pre-randomisation
Following consent, a baseline assessment will be under-
taken by a member of the trial team and entered onto
the appropriate case report form (CRF). This will
include:
1. Relevant medical history and physical examination,
to include the onset and nature of symptoms, type
of malignancy causing effusion (if known), pleural
procedures to date, current ECOG/WHO
performance status, current analgesia history and
current and projected treatment plan outside of
IPC-PLUS;
2. Results of standard blood tests (from within
24 hours);
3. Visual-Analogue Scale (VAS) score to assess
thoracic pain and breathlessness;
4. Quality of life assessment using EuroQol 5D
(EQ-5D) and Quality of Life Questionnaire C30
(QLQ-C30) health questionnaires;
5. Chest X-ray, ideally posterior-anterior (from within
previous 10 days) and
6. Thoracic ultrasound scan.
Patients will then be given an appointment, if this has
not already been provided, to have an IPC (PleurX® cath-
eter, CareFusion, IL, USA) inserted as a day case proced-
ure within one week of the baseline assessment.
IPCs must be placed by an appropriately trained mem-
ber of staff, but not necessarily a member of the trial
team. Immediately following drain placement, a thera-
peutic aspiration should be performed. During drainage,
patients should have pleural pressures measured after
every 100 to 200 mls of fluid removed, using a cali-
brated electronic pleural manometer (Mirador Biomedical,
Seattle, WA, USA). Pressure measurements should be
recorded along with the total volume removed. A chest X-
ray should be performed post-procedure to confirm ad-
equate drain placement.
Prior to discharge, the patient will be issued with a
drainage booklet which will act as a record for the vol-
umes of fluid drained throughout their period of trial
participation. They will also be given a chart on which
they can complete their own VAS scores for pain and
breathlessness, which should be done on a daily basis.
For the period post IPC insertion and before their ran-
domisation visit, patients should have their fluid drained
Table 1 Visit schedule
Timings
Event Pre-screening Consent/
baseline
IPC
insertion
Pre-randomisation Randomisation Follow-ups
(days post-randomisation)
On-going
14 28 42a 56a 70
Provide patient information
sheet
X
Sign consent X
Thoracic ultrasound X X X X X X X
Chest X-ray X X X X X X X
Standard blood tests X
Trial blood samples
(Southmead and Oxford only)
X
Trial pleural fluid samples
(Southmead and Oxford only)
X X X X X X X
Manometry X
Instillation of talc/placebo X
Community IPC drainages Xb X
Drainage booklet X X
Daily VAS scores X X X
Collection of VAS booklet X X X X X X
EQ-5D questionnaire X X X X X X X
QLQ-C30 questionnaire X X X X X X X
Patient diary X X
IPC = Indwelling pleural catheter.
VAS = Visual analogue scale.
EQ-5D = EuroQuol 5D.
QLQ-C30 = Quality of Life Questionnaire C30.
aVisits at days 42 and 56 may be done over the telephone and therefore the patient would not have a chest X-ray or thoracic ultrasound.
bMinimum of three drainages in the community between IPC insertion and randomisation.
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mediately after IPC insertion prior to discharge. This
first drainage may be to the maximum clinically appro-
priate volume, with subsequent drainages to a maximum
of 1,000 mls per drainage. The patient’s fifth drainage
can take place as part of their randomisation visit.
Patients will attend their local trial centre 10 days
(+/− one day, as above) after IPC insertion. Their pleural
space should be drained to dryness, or as close to dryness
as allowed by symptoms. Following this, they should
undergo a chest X-ray (ideally posterior-anterior) and have
an appointment with a member of the trial team, who will
perform a standardised medical assessment. Quality of life
will be assessed using the EQ-5D and QLQ-C30 question-
naires. The chest X-ray should be examined for evidence
of lung entrapment and significant fluid. A thoracic ultra-
sound of the side where the IPC has been inserted should
be performed, looking for evidence of fluid loculation and
septation.
If there is evidence of significant lung entrapment (de-
fined as >25% of the hemithorax without expanded lung
visible on a chest X-ray, as judged by two separateclinicians) or significant pleural fluid (defined as pleural
fluid, confirmed on thoracic ultrasound, occupying more
than one third of the hemithorax as judged by two sep-
arate clinicians using visual estimation on a chest X-ray),
then the patient should be excluded from randomisation.
Patients who do not meet the criteria for randomisation
should have their on-going care devolved to the appro-
priate local services. Patients may also be excluded for
other clinical reasons not relating to the degree of lung
entrapment or residual fluid. If a patient is eligible for
trial continuation at this point then they should be ran-
domised at the same visit and given the allocated treat-
ment substance before returning home.
Randomisation, blinding and emergency unblinding
Those who are eligible for will be randomly assigned in
a 1:1 ratio to either receive intrapleural talc slurry (4 g
Novatech Steritalc mixed with 50 mls 0.9% saline) via
the IPC, or to receive a placebo instillation of 0.9% ster-
ile saline alone.
Treatment allocation will be performed by an inde-
pendent computer randomisation service, which will be
Figure 1 Summary flow chart for IPC-PLUS trial. IPC = Indwelling pleural catheter, WHO/ECOG=World Health Organisation/Eastern Cooperative
Oncology Group, PS = Performance status, CXR = Chest X-ray, CT = Computed tomography, VAS = Visual analogue scale, SOB = Shortness of breath,
USS = Ultrasound scan.
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of recruitment centres following confirmation of suit-
ability for randomisation. Minimisation with a random
component will be used [19].
The minimisation factors are:
1. Volume of pleural fluid removed in the first 10 days
post IPC (≤1,999 mls or ≥2,000 mls),
2. Malignancy subtype (ovarian and breast,
mesothelioma or other), and
3. Day 10 chest X-ray appearance (expanded with no
evidence of trapped lung or evidence of trapped lung
but fits the criteria for randomisation).The study is to be performed in a single blind fashion.
Patients are to be kept unaware of their treatment allo-
cation, but the physician and other healthcare profes-
sionals involved with administering the slurry or placebo
are made aware of the allocation. A number of methods
are to be used to reduce the likelihood of a patient learn-
ing of their allocation. These include:
1. Making the randomisation phone call in a separate
room to the patient,
2. Preparing the slurry or placebo in a separate room
to the patient and ensuring materials are covered
before the patient is brought in,
Bhatnagar et al. Trials  (2015) 16:48 Page 7 of 133. Opaque syringes being used to make it less clear
which substance is being administered and
4. The slurry or placebo being administered from
behind the patient, with the patient facing forward.
Patients may have their treatment allocation revealed
(unblinded) at any time according to clinical need. A 24-
hour telephone number will be available for unblinding
queries.
Post-randomisation
The administration of the randomised substance should
be followed by an adequate flush to ensure as little as
possible is left in the IPC line. Patients should then be
observed for a minimum of two hours before being
discharged home. Observations should include at least
half-hourly measurements of pulse, blood pressure,
temperature, pain score and respiratory rate. Patients
must have their first post-randomisation drainage be-
tween 12 and 36 hours after instillation, and early com-
munication with community nursing teams is vital to
ensure this takes place.
Community drainage
Following randomisation, all patients should receive
fluid drainage in the community, although if necessary
patients may attend their local trial centre. Drainages
will be done by an appropriately trained healthcare pro-
fessional up to and including the day 28 follow-up visit.
After this, until the end of the trial follow-up period,
drainages may be performed by anyone with an appro-
priate level of training. This may include the patient’s
family or carers, but should not be the patient them-
selves. The frequency of drainage will be at the discre-
tion of the patient and community team, but should
occur at least twice per week, and should begin at three
times per week. Drainage volumes will be recorded on
each occasion.
Clinical assessments (days 14, 28, 42, 56 and 70
post-randomisation)
The follow-up period for each patient is 10 weeks post-
randomisation, or until death. During this time, the first
clinical assessment will occur 14 days after randomisa-
tion, and at two-weekly intervals thereafter. The ap-
pointments scheduled for days 42 and 56 may take place
over the telephone. Appointments on days 14, 28 and 70
must take place at the base hospital or satellite centre.
Face-to-face appointments (mandatory on days 14, 28
and 70, optional on days 42 and 56)
Before each assessment, but following arrival at the trial
centre, the patient’s IPC should be drained to dryness by
a trained member of staff. Patients should also have achest X-ray (ideally posterior-anterior) after they are
drained. The assessment should then be completed and
will include:
1. A record of any contact with medical services
including hospital admissions and length of stay,
outpatient care visit, emergency care visit and
ambulance service use Complications of IPC
placement through history and examination;
2. Documentation of analgesia requirements
(day 14 only);
3. Documentation of chemotherapy and/or
radiotherapy and any response;
4. Current ECOG/WHO performance status;
5. Quality of life assessments using EQ-5D and
QLQ-C30 health questionnaires and
6. A thoracic ultrasound scan, alongside completing
the ultrasound CRF.Telephone appointments (optional on days 42 and 56)
Any appointment which is to be performed over the
telephone should consist of the following:
1. A verbal reminder to the patient to complete and
send their quality of life questionnaires and VAS
booklets back to their local trial centre, ensuring
that a VAS score is completed during the telephone
consultation.
2. Completion of a specific telephone follow-up CRF
by the researcher, along with the standard health
service use CRF.
3. A review of drainage volumes with the patient over
the telephone.
If drainage volumes appear to have reduced to a level
suggesting pleurodesis, or if there is any suspicion of a
drainage or IPC complication, then the patient must
attend for the next scheduled follow-up visit. Alterna-
tively, a patient may attend the following day for a full
face-to-face visit, with the telephone follow-up being
discarded.Removal of drains
Once inserted, drains may be removed at any time at
the clinical discretion of the patient’s primary physician,
at the request of the patient or at the discretion of the
trial team. If a drain is to be removed, patients should
be given an appointment to have this done within
14 days of the clinical assessment at which this decision
was taken. Any patient who has a drain removed during
their post-randomisation trial period will continue to
undergo planned follow-up for the full 70 days.
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All care should be taken to ensure IPCs do not become
blocked, beginning with an adequate flush at the end of
sclerosant administration. If there is a suspicion that a
blockage has occurred then standard local unblocking
procedures should be followed.
Biological samples and storage
During the trial baseline assessment, all patients should
have standard blood tests for full blood count, urea and
electrolytes, liver function, clotting function and C-
reactive protein taken if there are no results available
from within the previous 24 hours. In addition to these,
at the research sites at North Bristol and Oxford, one
ethylenediaminetetraacetic acid (EDTA), one serum gel
tube and one citrate tube of blood should be taken.
During IPC insertion, one EDTA, one serum gel tube
and one citrate sample tube of pleural fluid should also
be collected from patients at the North Bristol and
Oxford sites. All such trial samples should be processed
and stored as per the appropriate standard operating
procedure.
At the North Bristol and Oxford research sites, prior
to each trial follow-up appointment (every two weeks
for 10 weeks), additional samples of pleural fluid should
be collected during IPC drainage, before being processed
and stored in the same manner as above.
Participants will give their permission for linked an-
onymous blood and pleural samples to be stored and
analysed at North Bristol NHS Trust (NBT), or, if from
another site, for those samples to be transferred to NBT
for storage and analysis. Samples will be stored in a ded-
icated freezer in the University of Bristol laboratory on
the NBT site. Samples will be stored, anonymised and
eventually destroyed in line with local policy.
Ultrasound scans
All ultrasound scans must be performed by fully trained
operators (with sufficient experience to scan and inter-
pret images independently) on the local research team.
Scans will be used to assess the presence and degree of
pleural fluid complexity, and fluid depth.
Visual Analogue Scale scoring
All patients will complete a VAS assessment of thoracic
pain and breathlessness during their baseline assess-
ment. After IPC insertion, beginning the following
morning, patients should repeat this assessment using
the documentation provided. VAS scores should then
be recorded on a daily basis for the duration of trial in-
volvement, with recordings being made each morning.
If IPC drainage is due to take place that day, then the
score should be noted before the drainage takes place.End of trial
The trial will cease recruitment once the target of 154 ran-
domised patients has been met, or if the Trial Steering
Committee feels the interim analysis after 100 patients
justifies early cessation. The provisional end of trial
date will therefore be 10 weeks after the randomisation
of the final trial patient. At the end of each patient’s
follow-up period they will be stratified as ‘alive’ or
‘dead’, and survival data collated. Further information
regarding participants’ health status and survival may
be obtained by accessing the NHS central register. This
will require consent to be given separate to trial in-
volvement. Those who still have an IPC in situ will have
their care devolved to the appropriate local services.
Patient withdrawal and loss to follow-up
Patients will have originally consented to trial follow-up
procedures, including sample collection, storage and
analysis where appropriate. Patients have the right to
withdraw from the trial at any point. A request by a pa-
tient to withdrawal does not have to be justified and will
not affect future or on-going care. In the event of with-
drawal, any details available regarding the reason(s)
should be recorded in the patient’s CRF. Patients may
still be stratified as ‘alive’ or ‘dead’ at the end of their
follow-up period, unless consent for clinical data use is
withdrawn. Patients who withdraw before randomisation
will not be included in the final analysis.
If a patient moves to an area outside of the trial centre
catchment, every effort should be made to continue
follow-up in conjunction with the new local services, or
via the new GP. If this cannot be done, the patient will
be recorded as ‘lost to follow-up’.
Data collection and statistical considerations
Data collection
Data will be collected according to the schedule de-
scribed above and in Table 2. Sites will enter data onto
CRFs, which will be checked by the trial coordination
centre before being entered onto an electronic database.
The following CRFs will be used during the trial: en-
rolment, baseline assessment, IPC insertion, day 10
assessment and randomisation, follow-up, telephone
follow-up, thoracic ultrasound appearances, health re-
source utilisation and withdrawal.
In addition to the above, patient data will also be col-
lected via a daily patient VAS score booklet and a daily
IPC drainage volume booklet.
Primary endpoint
The primary endpoint is the number of patients with
successful pleurodesis at 5 weeks post-randomisation.
For the primary outcome measure, successful pleurod-
esis will be defined as the collection of less than, or
Table 2 List of major protocol amendments
SA01 • Clarification of randomisation target of 154 patients
• All references to Short Form 36 Quality of Life (SF-36 QoL) questionnaire removed
• Added an exclusion criterion: patients must have access to phone for investigator trial contact
• Clarified sample collection and analysis
• Clarified procedure pre-randomisation
• Clarified that patients may also be excluded from randomisation for clinical reasons other than X-ray appearances
• Updated summary tables and clarified pre-randomisation day nomenclature
• Stipulated a time window in which patients must have first indwelling pleural catheter (IPC) drainage post-randomisation
• Clarified time window in which patients may have follow-up appointments
• Clarified wording in safety reporting section and highlighted expected minor side effects from talc
• Updated members of the Trial Steering Committee
• New sites added: Preston, Portsmouth and Bristol Royal Infirmary
SA02 • Change of principal investigator at Portsmouth site
SA03 • New sites added: Worcester, North Staffordshire, North Tyneside, Middlesbrough, South Manchester and Blackpool
• Creation of letter and short trial summary for district nurses
• Alteration to primary endpoint; changing minimal fluid volume required for pleurodesis from 20 to 50 mls
• Change to time limit given to patients to consider patient information sheet
• Removed requirement that trial chest X-ray must only be taken as a posterior-anterior image
• Trial flow chart updated, allowed patients to have follow-up appointments at satellite centres
• Allowance for patients to be approached as an inpatient but management must be as an outpatient for trial
• Clarifications to adverse event and serious adverse event reporting procedures
SA04 • New site added: Bath
SA05 • New sites added: London, Mansfield, Stockton-on-Tees and Sheffield
• Clarification of wording of primary endpoint, removal of duplicate secondary endpoint and addition of new secondary endpoint
• Clarification of definition of trapped lung in trial flow chart and protocol
• Addition of new QoL questionnaire (QLQ-C30) for all new trial participants
• Expanded the use of pleural manometry to all centres
• Removed the need for 0.9% saline placebo to be sourced from a particular manufacturer
• Updated wording of how the primary outcome will be analysed
• Updated membership of the Trial Steering Committee
SA06 • New sites added: Northampton, Ayr, Cambridge, Aintree and Hull
• Change of inclusion criteria to require World Health Organisation (WHO) performance of two or better to be eligible, three if
score will decrease to two after drainage.
• Allow patients with previous pleurodesis as long as longer than 56 days before trial entry
• Relax follow-up visits by allowing day 42 and 56 to be carried out over the telephone
• Allow carers or relatives to perform chest drains after the day 28 post-randomisation visit
• Extend recruitment period to May 2015
• Relaxation of manometry recordings from every 100 ml to every 100 to 200 ml
• Updated membership of the Trial Steering Committee
Bhatnagar et al. Trials  (2015) 16:48 Page 9 of 13equal to, 50 mls of pleural fluid on three consecutive oc-
casions, with chest opacification on the side of the IPC
less than 25%, as judged by two independent clinicians,
who should be blind to treatment allocation. Informa-
tion on drainage volumes will be collected in thecommunity and during follow-up visits as described
above. The X-ray for chest opacification must have been
taken after the third consecutive occasion of collection
of less than 50 mls of fluid, and within the 10-week
follow-up period. All three occasions of collection of less
Bhatnagar et al. Trials  (2015) 16:48 Page 10 of 13than 50 mls of fluid should also occur within the 10-
week follow-up period.
Patients who drain less than 50 mls of fluid on three
or more occasions but who continue to have greater
than 25% pleural opacification on a chest X-ray due to
pleural fluid (as proven by thoracic ultrasound), will be
defined as having an unsuccessful pleurodesis. If there is
a clinical suspicion that the drain may be blocked then
appropriate attempts to resolve this should be made
prior to a definition being made.
The achievement of pleurodesis should be dated to the
first drainage of less than or equal to 50 mls. Even if pa-
tients achieve the requirements for pleurodesis during
the trial period, they will continue to receive fortnightly
follow-up visits as originally planned until the 70-day
follow-up period is complete.
Patients who die during the 10-week trial period will
be assessed for whether they achieved pleurodesis suc-
cess prior to death. This requires the collection of less
than, or equal to, 50 mls of pleural fluid on three con-
secutive occasions, with chest opacification on the side
of the IPC less than 25%, as judged by two independent
clinicians, who should be blind to treatment allocation,
with the X-ray having been taken after the third con-
secutive collection volume of less than 50 mls.
Secondary endpoints
The secondary endpoints for this trial are as follows:
1. Self-reported quality of life status, measured at 14,
28, 42, 56 and 70 days, using the EQ-5D and
QLQ-C30 health questionnaires.
2. Self-reported VAS scores, measured daily from
randomisation to 10 weeks post-randomisation, for
thoracic pain and breathlessness.
3. Total volume of pleural fluid drained from
randomisation to 10 weeks post-randomisation.
4. All-cause mortality up to 10 weeks post-
randomisation.
5. Number of hospital inpatient bed-days required
from randomisation to 10 weeks post-randomisation.
6. Degree of loculation of pleural fluid following talc
instillation as judged by thoracic ultrasound and
septation score at two-weekly intervals for the
10-week follow-up period.
7. Pleurodesis success at 10 weeks post-randomisation,
as defined by consecutive fluid volume
measurement.
8. Number of pleural procedures to relieve pleural
fluid, excluding IPC drainage, from randomisation to
up to 10 weeks.
9. Pleurodesis success at five and 10 weeks post-
randomisation, as defined by total volume of fluid
collected over two consecutive weeks.As part of a secondary analysis, patients who have re-
corded drainages of less than or equal to a total of 250
mls of fluid over two consecutive weeks during their
follow-up period (with appropriate radiological findings)
will also be defined as having a successful pleurodesis.
The period of two consecutive weeks may begin with
any drainage which is undertaken during the post-
randomisation trial period, and ends two weeks later on
the same day of the week. The drainage volume re-
corded on this final day is included in the total volume
for the two-week period. Patients must be drained no
less frequently than twice per week.
In order to be defined as having a successful pleurod-
esis, a patient’s chest X-ray must have chest opacification
on the side of the IPC of less than 25%, as judged by two
independent clinicians, who should be blind to treat-
ment allocation. The X-ray for chest opacification must
have been taken after the last drainage of the two-week
period, and within the overall 10-week follow-up period.
For patients who successfully drain less than or equal
to 250 mls of fluid in a two-week period, the date of
pleurodesis is defined as the day of the first drainage in
that period. All drainages which count towards the total
volume must occur within the study period.
Patients who die during the follow-up period will also
be assessed for pleurodesis using measurements col-
lected prior to death. The clinical and radiological
parameters used to define successful pleurodesis by vol-
ume over time remain the same as those described
above.
Statistical analysis plan
The primary analysis will be by the intention-to-treat
principle and will include all randomised patients on
whom an outcome is available [20]. All tests will be
two-sided, and all analyses will be adjusted for the mini-
misation variables [21-24]. The primary outcome will be
analysed using a time-to-event regression model, which
will include mortality as a competing risk. The full stat-
istical analysis plan for the IPC-PLUS trial will be writ-
ten and ratified by the Trial Steering Committee prior
to data unblinding, and will be published in a separate
document.
Interim analysis
One interim analysis will be carried out after 100 pa-
tients are randomised in order to test for efficacy. The
O’Brien-Fleming stopping rule will be used, which re-
quires a P value of <0.005 for the primary endpoint in
order to stop the trial early [25]. If the trial is not
stopped at the interim analysis, the O’Brien-Fleming rule
requires a P value of <0.048 at the final analysis in order
to declare a statistically significant difference in the pri-
mary endpoint. The results of the interim analysis will
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mittee, who will make a recommendation to the Trial
Steering Committee as to whether the trial should stop
early. This recommendation will also take into consider-
ation other sources of evidence aside from the primary
endpoint, such as secondary outcomes and safety data.
Subsidiary studies
In addition to the primary and secondary endpoints
above, the trial will generate data to inform further sub-
studies. These will relate to the trial questions which are
not directly linked to the pleurodesis efficacy of talc, and
the details of their analysis are beyond the scope of this
protocol. Sub-studies will include the following:
1. Examining whether the measurement of pleural
elastance can be used to predict lung entrapment
(pleural manometry).
2. Examining whether serum levels of NT-pro BNP at
baseline are related to pleurodesis success.
3. Health economic analysis: the perspective adopted
in the economic analysis will be that of the English
National Health Service and Social Services. As a
result we will collect information on the following
resource use items:
a. Intervention costs: This will entail collecting
information on talc, consumables and staff time.
This information will be obtained by reviewing
hospital records. Should a significant between-
group difference in the rates of IPC blockage and
drain removal occur, these will also be included
in the intervention cost analysis.
b. Follow-up costs: This will entail collecting
information on patients’ use of hospital resources
after randomisation. Information collected will
include inpatient stays, outpatient services, use of
emergency departments and ambulance costs.
Information on inpatient stays will be obtained by
reviewing the administrative care records in each
of the participating centres.Trial infrastructure
The Trial Management Group is responsible for the day-
to-day management of the trial. The team is responsible
for all aspects of the project (such as recruitment rate,
budget management, protocol adherence and so forth)
and for ensuring appropriate action is taken to safeguard
trial participants and the quality of the study. The
Respiratory Research Unit at NBT will have responsibil-
ity for authorisation, good clinical practice (GCP) and
conduct, data integrity, data checking and database
integrity.
The Trial Steering Committee consists of both inde-
pendent members as well as researchers working on thetrial. The role of the Trial Steering Committee is to
provide overall supervision of the study and monitor
the progress of the trial to ensure that it is being con-
ducted in accordance with the protocol, relevant regu-
lations and the principles of GCP. The Sponsor will be
represented at Trial Steering Committee meetings but
may choose to devolve this responsibility to a named
representative.
The Independent Data Monitoring Committee is inde-
pendent of the trial investigators, and consists of two ex-
perienced physicians and a biostatistician. Its role is to
review study safety data at regular intervals, and to pro-
vide advice to the Trial Steering Committee as to
whether recruitment should continue.
Safety reporting
Standard definitions and medical judgement will be used
for the identification of adverse events, adverse reac-
tions, the expectedness and seriousness of these events
and any potential relationship to a trial intervention.
Due to the population of patients involved in the IPC-
PLUS trial, a high number of adverse events are to be
expected. Many of these will not be related to the inves-
tigational medicinal product administration or trial-
related procedures, but will be as a direct consequence
of the patient’s underlying malignancy. Other events
may occur as a result of a trial-related intervention, but
are well-documented and regarded as normal reactions
in the context of talc administration. Expected adverse
events in these settings are:
1. Death due to underlying malignancy;
2. Admission due to underlying malignancy;
3. New fever after instillation of slurry or placebo
(≥38°C);
4. New mild tachycardia after instillation of slurry or
placebo(≥20 beats per minute over baseline);
5. New pleuritic chest pain after instillation of slurry or
placebo, requiring simple analgesia (simple analgesia
is defined as any medication which is not a
morphine derivative or equivalent);
6. New tachypnoea after instillation of slurry or
placebo (increase in respiratory rate of five or more
breaths per minute over baseline) and
7. New hypoxia after instillation of slurry or placebo
(to saturation of ≤92% on air, or to a level requiring
additional supplemental oxygen).
If any doubt in the causality of an event exists the local
investigator should inform the trial coordinator who will
notify the chief investigator. Pharmaceutical companies
and/or other clinicians may be asked to advise in some
cases. In the case of discrepant views on causality be-
tween the local investigator and others, all parties will
Bhatnagar et al. Trials  (2015) 16:48 Page 12 of 13discuss the case. In the event that no agreement is made,
the MHRA will be informed of both points of view.
Discussion
The IPC-PLUS trial is a multicentre, randomised con-
trolled trial which has the potential to significantly affect
how patients with malignant pleural disease are treated.
Although the TIME2 study published by Davies et al.
suggested that first-line therapy for MPE might include
IPCs [4], they are currently viewed by many practitioners
as predominantly a second-line treatment in those pa-
tients who have not had success with a talc pleurodesis.
The combination of talc and an IPC has been used in
anecdotal reports, but this is the first study to examine
its utility in a robust way. Theoretically, the addition of
talc to an IPC should allow for pleurodesis rates similar
to that seen in bedside slurry to be maintained, but with
the added benefit of outpatient management. This ap-
proach is likely to be applicable to a wide range of pa-
tients, including those with shorter life expectancies,
those who want to minimise the duration of an IPC be-
ing in place or to those who have a strong preference for
talc therapy but do not want to spend time in hospital.
Given both the increasing use of IPCs worldwide and
the availability of talc as a sclerosing agent, a positive
trial outcome will likely have a global impact. A negative
trial outcome, or if it is shown that the addition of talc
via an IPC is detrimental to patients, would still be use-
ful information as there remains a dearth of knowledge
regarding this important population of patients.
Trial status
IPC-PLUS gained REC approval in May 2012 and
MHRA approval in June 2012. The first recruitment site
gained local approval in July 2012 and opened shortly
after. There are currently 16 active recruitment sites in
the United Kingdom, with a further three sites in the
set-up phase. Recruitment will only begin at future sites
once all necessary local approvals have been granted. As
of July 2014, the study has enrolled 98 patients with 60
randomisations. The trial is due to complete in May
2015.
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